Radiosurgery with Cyberknife M6

An effective and non-invasive treatment method for primary, recurrent and oligometastatic cancer
Therapy with the robotic radiosurgery CyberKnife M6 is:
  • an innovative approach of treatment contrary to the traditional paradigm – surgery, conventional radiotherapy or hormonal therapy (ADT);
  • very precise, fast, effective, and safe;
  • do not affect daily life.
The main goals of the therapy are:
  • to find tumor lesions in the patient’s body and inactivate them;
  • to prolong symptom-free and overall survival;
  • to preserve the existing quality of life.
Clinical trials confirm:
  • effective treatment for primary, recurrent or oligometastatic cancer;
  • safety, low toxicity, and high local control of metastases;
  • androgen deprivation therapy-free survival (ADT-FS) for 1-3 yrs.

How does the therapy work?

Robotic radiosurgery with the CyberKnife M6 system is a very precise radiotherapy method, destroying tumor cells with accurately targeted high-dose ionizing radiation, which damages the DNA of tumor cells, restricting the ability of cells to divide. Cancer cells gradually die and the body destroys them naturally. Cancer cells are replaced by inactive cells — connective or scar tissue. This approach enables exposure of the affected tissue while minimizing damage and saving the nearby tissue.

The primary therapy processes

  • Preparation for treatment sessions using the CyberKnife® M6 system is conducted on an outpatient basis at SRC Sigulda.
  • Placement of gold markers in tumor lesions. Low-invasive procedure performed in order to boost the accuracy of the robotic radiosurgery. Performed by urologist or radiation oncologist.
  • Preparatory works and accurate diagnostics with CT and MRI for visualization of prostate cells and cells affected by cancer.
  • Drawing up of final individual treatment plan by using the imaging data to determine locations of the target cells of cancer and critical nearby organs which are then uploaded to CyberKnife® robotic system.
  • Radiosurgery treatment course with system CyberKnife® M6 is performed every day over a course of a maximum of 5 days, each of them 50 to 60 minutes long.
  • Therapy conclusions (except epicrisis), recommendations for the first three months of the post-treatment period, as well as information about possible side effects.
Follow-up after treatment with CyberKnife® M6:
  • determination of the PSA level in accordance with our doctor’s instructions;
  • consultation (by phone or in an electronic form) on the prevention of side effects, if any;
  • prevention of side effects by medication if necessary.
Continuing treatment with CyberKnife® M6:
  • in case of treatment of a previously treated cancer, and if a recurrence or separate metastases in bones, soft tissue or in other parts are established, robotic radiosurgery with CyberKnife® M6 ensures high control of local recurrence and allows postponing of the hormone replacement therapy and extends symptom-free survival;
  • according to recent research results, treatment with CyberKnife M6 can postpone palliative androgen deprivation therapy up to few years without increase PSA level and grade II-III toxicity;
  • if necessary, treatment may be repeated.


Most patients, who receive CyberKnife therapy, do not face serious (grade II and III) side effects.
Around 20% of patients developed toxicity following treatment, which was classified as mild (grade I or grade II). In case of bone metastasis irradiation, patients reported mild grade I bone pain.  In case of treatment for nodal metastases some patients experienced grade I fatigue and diarrhoea or worsening of post-radical prostatectomy urinary incontinence.